Infliximab-rezisztens Crohn-beteg gyermek adalimumab-kezelése.

Translated title of the contribution: Adalimumab treatment in infliximab-resistant pediatric patient with Crohn's disease

Gábor Veres, Réka Putz, Dolóresz Szabó, Kriszta Molnár, Hedvig Bodánszky, Antal Dezsofi, András Arató

Research output: Contribution to journalArticle

5 Citations (Scopus)


Treatment with the chimeric monoclonal antibody (infliximab) is highly effective in refractory and fistulising Crohn's disease, nevertheless, infliximab resistance may occur. Authors report a 12-year-old boy with infliximab refractory luminal Crohn's disease including 3 active perianal fistulas. The patient was treated successfully with adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody. After 10 weeks of therapy, the previously high activity index returned to normal and the fistulas were closed. Quality of life using validated questionnaire improved significantly also. Adalimumab might be a suitable therapy even in pediatric Crohn's disease patients with infliximab resistance.

Translated title of the contributionAdalimumab treatment in infliximab-resistant pediatric patient with Crohn's disease
Original languageHungarian
Pages (from-to)1858-1860
Number of pages3
JournalOrvosi hetilap
Issue number40
Publication statusPublished - Oct 4 2009

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Adalimumab treatment in infliximab-resistant pediatric patient with Crohn's disease'. Together they form a unique fingerprint.

  • Cite this

    Veres, G., Putz, R., Szabó, D., Molnár, K., Bodánszky, H., Dezsofi, A., & Arató, A. (2009). Infliximab-rezisztens Crohn-beteg gyermek adalimumab-kezelése. Orvosi hetilap, 150(40), 1858-1860.